Skip to main content

Menu

BNF for Children July 2025 Update

This update contains 10 significant changes, 2 dose changes and 4 new monographs.

Significant Changes:

  • Antibacterials, principles of therapy: updated guidance on notifiable diseases.
  • Asthma, acute: update to criteria for severity of acute asthma attacks.
  • Immunisation schedule: updated guidance for immunisation against respiratory syncytial virus.
  • Ivacaftor with tezacaftor and elexacaftor (Kaftrio®): risk of psychological side effects [MHRA/CHM advice].
  • Ocular corticosteroids: cautions updated (advice in betamethasone, dexamethasone, fluorometholone, prednisolone; see example in fluorometholone).
  • Ocular NSAIDs: cautions updated (advice in diclofenac sodium, ketorolac trometamol; see example in diclofenac sodium).
  • Respiratory syncytial virus immunisation: updated guidance.
  • Salbutamol: reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines [MHRA/CHM advice].
  • Terbutaline sulfate: reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines [MHRA/CHM advice].
  • Thiopurines and intrahepatic cholestasis of pregnancy [MHRA/CHM advice] (advice in azathioprine, mercaptopurine, tioguanine; see example in azathioprine).

Dose Changes:

  • Palivizumab [update to indications and dose].
  • Pimecrolimus [update to dosing for short-term treatment of mild to moderate atopic eczema (including flares) when topical corticosteroids cannot be used].

New Monographs:

  • Abrysvo® [respiratory syncytial virus (RSV) vaccine].
  • Andembry® [garadacimab].
  • Artesunate.
  • Noxafil® [posaconazole].